Exact Sciences Shares Rise after Analyst Upgrade | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Exact Sciences climbed almost 16 percent today after investment firm Rodman & Renshaw upgraded its stock to Market Outperform from Perform.

Rodman & Renshaw also increased the 18-month price target on Exact Sciences' shares to $12 from $7. Shares of the company on Nasdaq closed at $7.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.